Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  clear cell renal cell carcinoma
Stage/Subtype:  clear cell renal cell carcinoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 40 for your search:
Start Over
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer Who Have No Evidence of Disease after Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: E2810, NCI-2012-00723, CDR0000730383, ECOG-E2810, NCT01575548
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AV-951-15-303, NCI-2016-00282, NCT02627963
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991003, NCI-2016-00392, 2015-002429-20, JAVELIN RENAL 101, NCT02684006
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-426, NCI-2016-01738, 163460, 2016-000588-17, NCT02853331
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: WO39210, NCI-2017-00191, 2016-001881-27, NCT03024996
Hydroxychloroquine and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT11PLK01, NCI-2012-00427, 11-080, 1302010628, NCT01550367
Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 191711, NCI-2012-01247, 13-069, NCT01684397
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RX-0201-P2-A-09, NCI-2014-02443, NCT02089334
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-029, NCI-2014-01328, 2013-004072-36, NCT02089685
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: X4P-001-RCCA, NCI-2016-00531, NCT02667886
Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CX-839-004, NCI-2016-00900, NCT02771626
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX014-01, NCI-2016-01448, NCT02837991
Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: X4P-001-RCCB, NCI-2016-01920, NCT02923531
Sitravatinib and Nivolumab in Treating Patients with Advanced or Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0332, NCI-2017-00324, NCT03015740
Axitinib and Nivolumab in Treating Patients with Advanced Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: GU-102, NCI-2017-01090, NCT03172754
Aldesleukin and Nivolumab in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2016.103, NCI-2017-01121, NCT02989714
Everolimus Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: H-23409, NCI-2012-00764, 06-08-20-01, NCT00831480
Pazopanib Hydrochloride or Temsirolimus in Treating Patients with Metastatic or Locally Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0358, NCI-2011-01277, NCT01392183
High-Dose Aldesleukin and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 012013-041, NCI-2015-01670, NCT01896271
Personalized Dose of Axitinib in Treating Patients with Previously Treated Locally Recurrent or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE7815, NCI-2016-00020, 15-1386, IRB# 15-1386, NCT02579811
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: C31005, NCI-2016-00540, 2015-002133-22, U1111-1172-1808, NCT02724020
Atezolizumab and Bevacizumab in Treating Patients with Advanced or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-592, NCI-2016-01017, NCT02724878
Nivolumab with or without Stereotactic Ablative Radiation Therapy in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 122015-052, NCI-2016-01284, NCT02781506
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-427, NCI-2016-02059, 2016-000589-47, NCT02853344
Start Over